GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+3.13%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$331M
AUM Growth
+$331M
(-37%)
Cap. Flow
-$195M
Cap. Flow
% of AUM
-58.77%
Top 10 Holdings %
Top 10 Hldgs %
59.58%
Holding
38
New
5
Increased
3
Reduced
19
Closed
9
Top Buys
| 1 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$12.6M |
| 2 |
Viridian Therapeutics
VRDN
|
$5.69M |
| 3 |
Unicycive Therapeutics
UNCY
|
$3.49M |
| 4 |
ProMIS Neurosciences
PMN
|
$3.49M |
| 5 |
Cartesian Therapeutics
RNAC
|
$3.22M |
Top Sells
| 1 |
Arcellx
ACLX
|
$32.7M |
| 2 |
UroGen Pharma
URGN
|
$27.3M |
| 3 |
Evolus
EOLS
|
$20.8M |
| 4 |
Insmed
INSM
|
$16.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$14.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurogene
NGNE
$264M
| $42.1M | 12.4% | 1,004,291 | – | – |
|
|
ABVX
2
Abivax
ABVX
$6.12B
| $24.5M | 7.22% | 2,128,773 -343,415 | -14% | -$3.96M |
|
3
Pliant Therapeutics
PLRX
$101M
| $21.4M | 6.3% | 1,910,121 -726,743 | -28% | -$8.15M |
|
|
4
Evolus
EOLS
$494M
| $19M | 5.58% | 1,170,000 -1,281,772 | -52% | -$20.8M |
|
|
5
Viridian Therapeutics
VRDN
$1.5B
| $17.1M | 5.02% | 750,000 +250,000 | +50% | +$5.69M |
|
6
Cytokinetics
CYTK
$4.23B
| $16.7M | 4.91% | 316,000 -158,202 | -33% | -$8.35M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $15M | 4.43% | 1,299,503 -39,065 | -3% | -$452K |
|
8
Dynavax Technologies
DVAX
$1.19B
| $14.8M | 4.35% | 1,326,234 -1,047,766 | -44% | -$11.7M |
|
9
Context Therapeutics
CNTX
$75.4M
| $13.6M | 4% | 6,934,982 -484,373 | -7% | -$949K |
|
10
Zura Bio
ZURA
$133M
| $13.3M | 3.9% | 3,263,672 -1,378,569 | -30% | -$5.6M |
|
|
ORKA
11
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $12.6M | 3.71% | +514,659 | New | +$12.6M |
|
12
Merus
MRUS
$4.98B
| $12.5M | 3.68% | 250,000 -273,288 | -52% | -$13.7M |
|
13
Olema Pharmaceuticals
OLMA
$375M
| $11.9M | 3.51% | 1,000,000 +203,120 | +25% | +$2.43M |
|
14
Ionis Pharmaceuticals
IONS
$6.79B
| $10.2M | 3.01% | 255,000 -75,000 | -23% | -$3M |
|
|
AUTL
15
Autolus Therapeutics
AUTL
$399M
| $10.2M | 3% | 2,811,955 -629,712 | -18% | -$2.29M |
|
|
16
UroGen Pharma
URGN
$900M
| $9.64M | 2.84% | 758,786 -2,147,473 | -74% | -$27.3M |
|
|
OPTN
17
DELISTED
OptiNose
OPTN
| $8.62M | 2.54% | 12,861,136 -865,961 | -6% | -$580K |
|
|
18
Arcellx
ACLX
$3.85B
| $8.35M | 2.46% | 100,000 -392,000 | -80% | -$32.7M |
|
19
Dianthus Therapeutics
DNTH
$759M
| $7.53M | 2.22% | 275,000 -482,929 | -64% | -$13.2M |
|
20
Outlook Therapeutics
OTLK
$37.8M
| $6.9M | 2.03% | 1,293,028 -408,482 | -24% | -$2.18M |
|
21
Jasper Therapeutics
JSPR
$45.5M
| $6.06M | 1.78% | 322,380 -79,635 | -20% | -$1.5M |
|
22
Voyager Therapeutics
VYGR
$186M
| $5.62M | 1.65% | 959,953 -641,574 | -40% | -$3.75M |
|
|
BBOT
23
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $5.22M | 1.54% | 500,000 | – | – |
|
24
TScan Therapeutics
TCRX
$102M
| $5.06M | 1.49% | 1,016,375 +75,544 | +8% | +$376K |
|
|
25
Unicycive Therapeutics
UNCY
$74M
| $3.49M | 1.03% | +8,559,000 | New | +$3.49M |
|